Latest

pharmacology

·May 24, 2020·5 min read

Preventing ‘cytokine storm’ may ease severe COVID-19 symptoms

Treating coronavirus patients with alpha-blockers may help prevent the cytokine storm associated with severe COVID-19 infection. Alpha-blockers interfere with the cell signaling that triggers cytokine storms. Mice with bacterial infections that were treated with alpha-blockers experienced reduced cytokine storms and decreased death rates.

Featured Neuroscience Open Neuroscience Articles

·May 18, 2020·3 min read

Antiviral drug can speed up recovery of COVID-19 patient

Interferon-a2b an antiviral treatment shows promise in helping to speed up the recovery of patients with severe COVID-19 infections. IFN-a2b improves viral clearance and decreases the levels of inflammatory markers in coronavirus patients.

Featured Neuroscience Open Neuroscience Articles

·May 14, 2020·4 min read

Evidence Does Not Support Chloroquine or HCQ Use Alone or in Combination with Azithromycin as Prophylaxis for COVID-19

Researchers find no beneficial evidence to support the use of chloroquine or hydroxychloroquine, either used alone or in combination with azithromycin, for the treatment of COVID-19.

Featured Neuroscience Open Neuroscience Articles

·May 14, 2020·4 min read

Arthritis drug Anakinra may improve respiratory function in some patients with severe COVID-19

Anakinra, a clinically approved anti-inflammatory used to treat rheumatoid arthritis, improves respiratory function in patients with severe COVID-19 infection.

This shows someone holding a box of actemra

Featured Neurology Neuroscience

·May 3, 2020·2 min read

Arthritis Drug Presents Promise as Treatment for COVID-19 Pneumonia

UCSD has launched a Phase III clinical trial to assess whether tocilizumab (Actemra), a drug commonly prescribed for rheumatoid arthritis and other inflammatory disorders, has therapeutic value for those at risk of developing severe COVID-19 infection. The drug is a monoclonal antibody-based therapy that blocks receptors for interleukin-6, a cytokine that triggers inflammation as an early immune response to coronavirus. Blocking IL-6 could prevent the risk of the COVID-19 associated cytokine storm many with severe infection experience.

Featured Neuroscience Open Neuroscience Articles

·May 1, 2020·3 min read

Scientists uncover structural basis for SARS-CoV-2 inhibition by Remdesivir

Researchers have identified the structural basis for SARS-CoV-2 inhibition by the drug Remdesivir. The findings reveal a potential binding pattern that offers support for the design of new, more efficient, and specific anti-COVID-19 drugs.

Featured Neuroscience

·April 30, 2020·5 min read

Experts warn against malarial drugs as a cure for coronavirus

Researchers warn early encouraging signals from small-scale preliminary trials for the use of hydroxychloroquine to treat coronavirus should be taken with caution. Current evidence suggests chloroquine and hydroxychloroquine can not be used as a general treatment for all COVID-19 infections. Researchers say the medications should be restricted for the treatment of COVID-19 patients with pneumonia and high death risk, and only then as part of a clinical trial. The study also points out the negative side effects produced by the anti-malarial drugs and warns that those who need the medication to treat Lupus might not have access to treatment if widespread use for coronavirus occurs. The study reports there is no evidence to support the mass use of chloroquine or hydroxychloroquine to prevent infection from occurring.

Featured Neuroscience Open Neuroscience Articles

·April 25, 2020·3 min read

Novel Compounds Designed To Inhibit SARS-CoV-2 Main Protease

Researchers have developed two new compounds that are able to inhibit SARS-CoV-2 main protease. The study reports one of the compounds is a strong drug candidate for further investigative trials in the treatment of coronavirus.

Featured Genetics Neuroscience

·April 24, 2020·3 min read

Asthma drug in clinical trial to treat severe COVID-19 patients

A new clinical trial is underway to test ibudilast, an asthma drug approved in Japan, for the treatment of severe COVID-19. Ibudilast is a MIF inhibitor. MIF is a gene that regulates immune response and is a driver of inflammation which results in the cytokine storm associated with coronavirus.

Featured Neuroscience

·April 20, 2020·3 min read

Remdesivir prevents disease progression in monkeys with COVID-19

Macaque monkeys infected with mild-to-moderate coronavirus responded well to the antiviral Remdesivir. Researchers report the monkeys showed reduced clinical symptoms and less lung damage when the drug was administered. The findings back up other reports which claim the drug is effective at treating human COVID-19 infections in current clinical trials.

Featured Neuroscience Neuroscience Videos

·April 20, 2020·7 min read

Live virus used to identify 30 existing drugs that could successfully treat COVID-19

27 existing drugs which are currently not under evaluation for COVID-19 are effective at halting the replication of SARS-CoV-2. Four of the drugs, apilimod, MLN-3897, VBY-825, and ONO 5334, which have previously been tested for the treatment of a range of diseases from rheumatoid arthritis to cancer, appear to be the best candidates for coronavirus treatment.

Featured Neuroscience

·April 13, 2020·4 min read

Remdesivir effective against a key enzyme of coronavirus that causes COVID-19

Remdesivir, a drug initially developed to fight Ebola and currently being fast-tracked into trials for COVID-19, is highly effective at stopping the replication mechanism of coronavirus. The drug tricks the virus by mimicking its building blocks, causing the inhibitor to get incorporated repeatedly, and preventing replication of SARS-CoV-2.

1 2 3 4 5 … 20

pharmacology

Preventing ‘cytokine storm’ may ease severe COVID-19 symptoms

Antiviral drug can speed up recovery of COVID-19 patient

Evidence Does Not Support Chloroquine or HCQ Use Alone or in Combination with Azithromycin as Prophylaxis for COVID-19

Arthritis drug Anakinra may improve respiratory function in some patients with severe COVID-19

Arthritis Drug Presents Promise as Treatment for COVID-19 Pneumonia

Scientists uncover structural basis for SARS-CoV-2 inhibition by Remdesivir

Experts warn against malarial drugs as a cure for coronavirus

Novel Compounds Designed To Inhibit SARS-CoV-2 Main Protease

Asthma drug in clinical trial to treat severe COVID-19 patients

Remdesivir prevents disease progression in monkeys with COVID-19

Live virus used to identify 30 existing drugs that could successfully treat COVID-19

Remdesivir effective against a key enzyme of coronavirus that causes COVID-19

Dual Brain-Machine Interfaces Unlock Bionic Hand Kinesthesia

Overcoming Endothelial Sorting to Cure Glioblastoma

Hybrid VR and Nerve Stimulation Doubles Stroke Recovery

150-Year-Old Neuroanatomy Mystery Confirmed via MRI

Subscribe